Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (March 2026)
21 slides from Neurotech International's investor presentation, Mar 18, 2026
Slide 1: Redefining Treatment for Neurodevelopmental Disorders
Redefining Treatment for For personal use only Neurodevelopmental Disorders Corporate Overview Dr Anthony Filippis Chief Executive Officer & Managing Director March 2026 | ASX: NTI 0
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward looking statements. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guida
Slide 3: Neurotech: a high value investment opportunity
Neurotech: a high value investment opportunity For personal use only Neurotech is an ASX-listed (ASX: NTI) clinical-stage Neurotech is developing NTI164 as a novel therapy With four completed clinical trials across three biotech company for childhood neurological and neurodevelopmental indications,
Slide 4: Targeting high impact indications where there is a clear unmet market need
Targeting high impact indications where there is a clear unmet market need autism spectrum disorder (ASD) • High unmet need for safe, effective For personal use only treatments for core symptoms • 1 in 31 children (US) • Current market ~US$3B[2] and growing • Boys 4x more likely to be diagnosed • Gr
Slide 5: Neurotech's pipeline comprises clinical programs in neurodevelopmental disorders of children
Neurotech’s pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved For personal use only NTI164 Targets neuroinflammation PRECLIN. PHAS E 1 PHAS E 2 PHASE 3 MARKET Neurodevelopmental disorders PI: Phase I/II data Autism Spectrum Disorder
Slide 6: What is NTI164?
What is NTI164? For personal use only ❶ Disease-modifying transformative therapy ❼ Safe and effective in non-clinical and in neurodevelopmental disorders clinical studies; backed by clinical data and open to partnering opportunities ❷ Standardised, pharma-grade CNS modulator, ❻ Patent applications c
Slide 7: NTI164 – Clinical Data Demonstrated Improvements (ASD)
NTI164 – Clinical Data Demonstrated Improvements Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families. For personal use only THE FOU R P IL LA RS O F C HA NGE Phase II/III HARMONY Autism Spectrum Disorder Clinical Trial GL
Slide 8: Approval for Phase III BEYOND HARMONY clinical trial in ASD
ILLUSTRATIVE Approval for Phase III BEYOND HARMONY clinical trial in ASD use only Patient Population: Placebo n = 75* Follow-Up RANDOMISATION Blinded Treatment For personal SCREENING • ASD Level II or III Period Open-Label Extension • Total 24-week • 5 – 17 years of age Period duration • Stable ther
Slide 9: ASD Phase III roadmap and value inflection points
ASD Phase III roadmap and value inflection points f_trecens arma! | CIM TC DUE HREC (e) ethics approval Patient recruitment Phase Ill clinical data Mid CY26 Phase III program supported by clinical data: Statistically significant and clinically meaningful Phase II/III efficacy signals Consistent safe
Slide 10: NTI164 – Clinical Data Demonstrated Improvements (Rett syndrome)
NTI164 – Clinical Data Demonstrated Improvements Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families. For personal use only THE FOU R P IL LA RS O F C HA NGE Granted Orphan Phase I/II Rett Syndrome Clinical Trial Drug Desi
Slide 11: Rare paediatric disease Priority Review Voucher re-instated
Rare paediatric disease Priority Review Voucher re-instated For personal use only • The Rare Pediatric Disease Priority Review Voucher (PRV) program sunset on 20 December 2024, causing a period of uncertainty for rare disease drug developers • Companies could still apply for Rare Pediatric Disease D
Slide 12: NTI164 – Clinical Data Demonstrated Improvements (Rett syndrome)
NTI164 – Clinical Data Demonstrated Improvements Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families. For personal use only THE FOU R P IL LA RS O F C HA NGE Granted Orphan Phase I/II Rett Syndrome Clinical Trial Drug Desi
Slide 13: The competitive landscape is not crowded with few approved therapies
The competitive landscape is not crowded with few approved therapies Early Development Late Development Approved Risperdal firstly developed by For personal use only Autism Spectrum Disorder NTI164 Janssen-Cilag & Ablify by Otsuka Several off-label use of other neuropsychiatric drugs which Originall
Slide 14: Market comparators provide a strong precedent for NTI164
AS AT 20 FEB 2026 Market comparators provide a strong precedent for NTI164 Market comparators Company Comparable pipeline Market Cap For personal use only (cannabidiol, approved) ~ US$10.3B (approved) ~ US$4.1B NNZ-2591 Phase 2 data including Angelman, Phelan McDermid, Pitt Hopkins ~AU$1.7B Anavex 2
Slide 15: Broad outreach program to nurture potential future partners for NTI164
The company has commenced a broad outreach program to socialise and nurture potential future partners for NTI164 Benchmarks for Phase II/III Neuro Disease Partnering For personal use only Typical Structure of Pharma Partnering Transactions Transactions (2016 – 2025 YTD) (n=64) Low Median High Upfron
Slide 16: Partnering opportunity for NTI164 is substantial
Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential Licensing Transactions Licensee Licensor Key Asset(s) Key Indication(s) Stage Date Deal Value (US$) For personal use only PTC518 Huntington’s disease Phase II Nov 2024 $2.9B ABV-1504/
Slide 17: Bringing botanical medicines to market: it can be done
Bringing botanical medicines to market: it can be done FDA-approved botanical prescription drugs For personal use only Active FDA Drug name Botanical source Indication(s) Notes ingredient(s) approval Camellia sinesis (green First FDA approved botanical ointment; standardised Veregen® Sinecatechins G
Slide 18: Neurotech Board and management bring extensive international experience
Neurotech Board and management bring extensive international experience in drug development, finance and commercialisation For personal use only Mr Mark Davies Dr Anthony Filippis Mr Max Johnston Board Chair Managing Director & CEO Non-Executive Director Over 25 years Over 25 years of life Over 40 y
Slide 19: Neurotech financial position and value drivers
AS AT 20 FEB 2026 Neurotech financial position and value drivers Corporate Fundamentals For personal use only Market Capitalisation: ~AU$ 18.2M Primary Listing: ASX: NTI Huge Market Potential Shares on Issue: 1.30 Billion Addressing high-growth neurological markets Proven science and de-risked progr
Slide 20: Value-driving catalysts on the horizon
Value-driving catalysts on the horizon For personal use only CY2026 Human Research Ethics Committee approval for ASD registration-enabling study 1Q CY2026 Initiation of first clinical site 1Q CY2026 First patient enrolled in ASD clinical trial Mid CY2026 Long-term chronic toxicology data Mid CY2026
Slide 21: Thank You & Contact Details
Thank You & Contact Details For personal use only Neurotech Investor Relations: info@neurotechinternational.com www.neurotechinternational.com Neurotech International Limited (ASX: NTI) This presentation This presentation was approved has been authorised for of by the Board release byInternational N
Neurotech International — Investor Presentation (March 2026) on 6ix